| Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS |
LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting in Montreal, Quebec and at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, California. |
globenewswire.com |
2025-05-15 10:00:00 |
Czytaj oryginał (ang.) |
| Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award |
LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner. |
globenewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Q1 2025 Earnings Call Transcript |
Biodesix, Inc. (NASDAQ:BDSX ) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Andrew Brackmann - William Blair Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Genuity Thomas Flaten - Lake Street Capital Markets Bill Bonello - Craig-Hallum Operator Good day and thank you for standing by. Welcome to the Biodesix's Q1 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-14 00:22:08 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates |
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2025-05-13 22:15:35 |
Czytaj oryginał (ang.) |
| Biodesix Announces First Quarter 2025 Results and Highlights |
Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025 ; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo. |
globenewswire.com |
2025-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 |
LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. |
globenewswire.com |
2025-04-29 10:00:00 |
Czytaj oryginał (ang.) |
| Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types |
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology |
globenewswire.com |
2025-04-23 10:00:00 |
Czytaj oryginał (ang.) |
| Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock? |
Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-03-06 15:06:18 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Q4 2024 Earnings Call Transcript |
Biodesix, Inc. (NASDAQ:BDSX ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Dan Brennan - TD Cowen Thomas Flaten - Lake Street Capital Markets William Bonello - Craig-Hallum Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Biodesix's Q4 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-03 22:06:21 |
Czytaj oryginał (ang.) |
| Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results |
Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023 ; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo. |
globenewswire.com |
2025-03-03 18:01:00 |
Czytaj oryginał (ang.) |
| Biodesix to Present at TD Cowen 45th Annual Health Care Conference |
BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD Cowen 45th Annual Health Care Conference on March 5, 2025. |
globenewswire.com |
2025-02-26 08:00:00 |
Czytaj oryginał (ang.) |
| Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 |
BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of trading on Monday, March 3. |
globenewswire.com |
2025-02-18 08:00:00 |
Czytaj oryginał (ang.) |
| Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) |
Grew full-year revenue to an estimated $71.3 million, an increase of 45% Grew full-year revenue to an estimated $71.3 million, an increase of 45% |
globenewswire.com |
2025-01-10 08:00:00 |
Czytaj oryginał (ang.) |
| BDSX Stock Rises After Publication of Study Data for Nodify CDT Test |
Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal. |
zacks.com |
2025-01-08 10:31:08 |
Czytaj oryginał (ang.) |
| Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study |
Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performance |
globenewswire.com |
2025-01-07 08:00:00 |
Czytaj oryginał (ang.) |
| Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-11-20 12:35:27 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript |
Biodesix, Inc. (NASDAQ:BDSX ) Q3 2024 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Sung Ji Nam - Scotia Bank Bill Bonello - Craig-Hallum Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to Biodesix, Inc. Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-01 17:29:09 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates |
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago. |
zacks.com |
2024-11-01 10:16:08 |
Czytaj oryginał (ang.) |
| Biodesix Announces Third Quarter 2024 Results and Highlights |
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo. |
globenewswire.com |
2024-11-01 08:00:00 |
Czytaj oryginał (ang.) |
| Biodesix to Participate in Three Investor Conferences in November |
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences: |
globenewswire.com |
2024-10-29 08:00:00 |
Czytaj oryginał (ang.) |
| Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024 |
LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday, November 1. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webca. |
businesswire.com |
2024-10-18 10:00:00 |
Czytaj oryginał (ang.) |
| Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study |
LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston, Massachusetts on Tuesday, October 8 at 10:20 am ET. The presentation will detail the experience of healthcare providers using the Nodify Lung® Nodule Risk Assessment in over 35,000 patients consecutively tested in a real-world clinical setting. Guidelines recommend that. |
businesswire.com |
2024-10-07 10:00:00 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Q2 2024 Earnings Call Transcript |
Biodesix, Inc. (NASDAQ:BDSX ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Chris Brinzey - IR Scott Hutton - CEO Robin Harper Cowie - CFO Conference Call Participants Andrew Brackmann - William Blair Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Biodesix Q2 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-08 00:52:09 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates |
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago. |
zacks.com |
2024-08-07 23:05:56 |
Czytaj oryginał (ang.) |
| Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E |
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX). |
zacks.com |
2024-06-27 13:06:32 |
Czytaj oryginał (ang.) |
| Biodesix Named to Inc. Magazine's 2024 “Best Workplaces” |
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Workplaces list. The ranking is a result of a comprehensive, data-driven measurement process to identify which American companies have excelled in creating exceptional workplaces with great company cultures. After collecting data from thousands of submissions, Inc. selected 543 honorees this year. Each company that was nomina. |
businesswire.com |
2024-06-18 12:13:00 |
Czytaj oryginał (ang.) |
| Biodesix to Participate in Two Investor Conferences in June |
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44th Annual Growth Stock Conference Presentation and 1x1 Meetings Presentation Date and Time: Tuesday, June 4, 2024 at 10:40 AM CT Location: Chicago, IL Jefferies Global Healthcare Conference Presentation and 1x1 Meetings Presentation Date. |
businesswire.com |
2024-05-28 10:00:00 |
Czytaj oryginał (ang.) |
| Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting |
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society (ATS) International Conference in San Diego, California. The presentation, titled "Performance comparison of a blood-based integrated classifier for lung nodule risk stratification in patients with versus without emphysema," will be presented by Arthur Romero MD, MSC, FCCP, As. |
businesswire.com |
2024-05-21 10:00:00 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Q1 2024 Earnings Call Transcript |
Biodesix, Inc. (NASDAQ:BDSX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Scott Hutton - CEO Robin Harper Cowie - CFO Chris Brinzey - IR Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Genuity Thomas Flaten - Lake Street Capital Markets Operator Welcome to the Biodesix Q1 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. |
seekingalpha.com |
2024-05-10 05:06:03 |
Czytaj oryginał (ang.) |
| Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates |
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2024-05-08 22:21:13 |
Czytaj oryginał (ang.) |
| Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference |
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the 2024 RBCCM Global Healthcare Conference, which will be held from May 14-15, 2024. 2024 RBCCM Global Healthcare Conference Fireside Chat Date: Tuesday, May 14, 2024 Fireside Chat Time: 1:35 PM ET Location: InterContinental New York. |
businesswire.com |
2024-05-07 10:00:00 |
Czytaj oryginał (ang.) |
| Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 |
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix's management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast vi. |
businesswire.com |
2024-04-24 10:00:00 |
Czytaj oryginał (ang.) |
| Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting |
LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical s. |
businesswire.com |
2024-04-09 21:00:00 |
Czytaj oryginał (ang.) |
| Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement |
LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share. Subject to. |
businesswire.com |
2024-04-05 11:17:00 |
Czytaj oryginał (ang.) |
| Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center |
LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer. Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with t. |
businesswire.com |
2024-03-25 08:00:00 |
Czytaj oryginał (ang.) |